Taken together, these data demonstrate a requirement for ST6GAL1-cGMP/PKG signaling axis in oncogenic properties of E6 and supports its inhibition as a viable therapeutic strategy against cervical cancer. The gene discussed is ST6GAL1; the disease is cervical cancer.